关于MDM2-p53蛋白与蛋白相互作用的小分子抑制剂的研究进展
Meiyao Hu1, Chang Xu1, Mingxin Xu1
1School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products; Kunming Medical University, 1168 Western Chunrong Road, Yuhua Street, Chenggong District, Kunming City, Yunnan 650500, P. R. China.
Anti-cancer agents in medicinal chemistry
|February 28, 2025
概括
抑制MDM2-p53相互作用的小分子可以恢复p53蛋白的瘤抑制功能. 本综述详细介绍了各种抑制剂支架及其抗癌潜力,强调了正在进行的研究挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 蛋白质p53是一个关键的瘤抑制剂,但它的功能被MDM2抑制.
- MDM2负面调节p53的稳定性和活性,导致癌症的发展.
- 针对MDM2-p53相互作用是一种有前途的抗癌策略.
研究的目的:
- 审查MDM2-p53蛋白质与蛋白质相互作用 (PPI) 的小分子抑制剂的最新进展.
- 总结各种结构性支架,它们的设计,合成和生物评估.
- 突出结构与活动的关系以及该领域正在进行的研究工作.
主要方法:
- 对针对MDM2-p53 PPI的小分子抑制剂的综合文献综述.
- 基于结构支架的抑制剂的分类 (例如,伊米达林,螺旋氧,罗利丁).
- 对关于抑制剂有效性和发展的临床前和临床数据的分析.
主要成果:
- 许多针对MDM2-p53 PPI的小分子抑制剂已经开发出了各种结构性支架.
- 这些抑制剂在临床前研究中表现出显著的抗癌疗效.
- 几种抑制剂已进入临床试验阶段,但尚未获得批准.
结论:
- 小分子抑制剂的MDM2-p53 PPI代表了癌症治疗的可行治疗策略.
- 在优化抑制剂亲和力,透性和整体疗效方面仍然存在挑战.
- 持续的研究是克服这些障碍和推进药物开发的关键.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


